化合物Belnacasan T6090
面议
- TargetMol
- 生产商
- 进口
- 美国
- 现货
- 全国
- 9
- 0
Product IntroductionBioactivity英文名: Belnacasan描述: Belnacasan (VX-765) 是一种具有口服活性的 IL 转换酶/caspase-1 抑制剂，是 VRT-043198 的口服生物活
AI问答
配套的仪器设备？
可以搭配的相关耗材试剂？
耗材描述
Product Introduction
Bioactivity
英文名: Belnacasan
描述: Belnacasan (VX-765) 是一种具有口服活性的 IL 转换酶/caspase-1 抑制剂，是 VRT-043198 的口服生物活性前药，作用于外周血单核细胞，可抑制 LPS 诱导的 IL-1β 和 IL-18 释放。
细胞实验: VX-765 is solubilized in DMSO and stored, and then diluted with RPMI 1640 complete medium (DMSO 0.2%) before use[1]. A total of 2×105 cells/well (100 μL cell suspension) is distributed in triplicate in flat-bottom 96-well plates. Either 50 μL of VX-765 (40 μM in RPMI 1640 complete medium containing 0.2% DMSO) or vehicle control is added to appropriate wells. Following a 30-min incubation at 37°C, 50 μL of LPS diluted in RPMI 1640 complete medium is added at final concentrations varying from 0.001 to 10 ng/mL. Cells are returned to a 37°C incubator. At 4 h after LPS addition, 75 μL of supernatant is removed from wells, cleared by centrifugation for 5 min at 1500 rpm, and stored at 4°C until assayed. Cells are returned to a 37°C incubator until 24 h after LPS addition, at which time 100 μL of supernatant is removed, cleared by centrifugation, and stored at 4°C. Supernatants are tested using ELISA kits for IL-1β, IL-6, IL-18, and IL-1α[1].
激酶实验: Enzyme inhibition is assayed by tracking of the rate of hydrolysis of an appropriate substrate labeled with either p-nitroaniline or aminomethyl coumarin (AMC) as follows: ICE/caspase-1, suc-YVAD-p-nitroanilide; caspase-4, Ac-WEHD-AMC; caspase-6, Ac-VEID-AMC; caspase-3, -7, -8, and -9, Ac-DEVD-AMC; and granzyme B, Ac-IEPD-AMC. Enzymes and substrates are incubated in a reaction buffer [10 mM Tris, pH 7.5, 0.1% (w/v) CHAPS, 1 mM dithiothreitol, and 5% (v/v) DMSO] for 10 min at 37°C. Glycerol is added to the buffer at 8% (v/v) for caspase-3, -6, and -9 and granzyme B to improve stability of enzymes. The rate of substrate hydrolysis is monitored using a fluorometer. Assays for cathepsin B and trypsin are performed[2].
体外活性: VX-765通过防止前脑星形胶质细胞中IL-1β的增加阻断大鼠体内的癫痫发生,而对后放电持续时间没有明显影响.在患有遗传性失神癫痫的成年大鼠体内注射3天VX-765后,通过选择性阻断IL-1β生物合成,明显降低累积持续时间,减少平均55%的棘慢波放电.50 mg/kg-200 mg/kg VX-765在急性癫痫小鼠模型中,通过延迟首次癫痫开始时间,并减少平均50%的癫痫发作次数以及64%的总持续时间,产生抗癫痫作用.200 mg/kg VX-765在胶原诱导的关节炎小鼠模型中,抑制60%脂多糖诱导的IL-1β产生,并导致炎症评分剂量依赖性明显降低,有效保护关节病变.
体内活性: VRT-043198会抑制IL-1β从外周血单个核细胞和全血中的释放,IC50分别为0.67 μM和1.9 μM。VX-765是一种口服可吸收的VRT-043198前药,显示出对ICE /半胱天冬酶-1和半胱天冬酶-4的有效抑制作用,Ki分别为0.8 nM和<0.6 nM。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: 5% DMSO+95% Saline : 4.65 mg/mL (9.14 mM, suspension)
Ethanol : 93 mg/mL (182.7 mM)
DMSO : 45 mg/mL (88.41 mM)
关键字: Inhibitor | VX 765 | VX765 | Belnacasan | inhibit | Caspase
相关产品: Taurodeoxycholic acid sodium hydrate | Excisanin A | Z-WEHD-FMK | Effusanin E | Soyasaponin Bb | 2',3'-Dehydrosalannol | Lucidenic acid B | SDZ 224-015 | Phenoxodiol | 5,7,4'-Trimethoxyflavone
相关库: Anti-Aging Compound Library | Drug Repurposing Compound Library | ReFRAME Related Library | Pyroptosis Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Human Metabolite Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library
Bioactivity
英文名: Belnacasan
描述: Belnacasan (VX-765) 是一种具有口服活性的 IL 转换酶/caspase-1 抑制剂，是 VRT-043198 的口服生物活性前药，作用于外周血单核细胞，可抑制 LPS 诱导的 IL-1β 和 IL-18 释放。
细胞实验: VX-765 is solubilized in DMSO and stored, and then diluted with RPMI 1640 complete medium (DMSO 0.2%) before use[1]. A total of 2×105 cells/well (100 μL cell suspension) is distributed in triplicate in flat-bottom 96-well plates. Either 50 μL of VX-765 (40 μM in RPMI 1640 complete medium containing 0.2% DMSO) or vehicle control is added to appropriate wells. Following a 30-min incubation at 37°C, 50 μL of LPS diluted in RPMI 1640 complete medium is added at final concentrations varying from 0.001 to 10 ng/mL. Cells are returned to a 37°C incubator. At 4 h after LPS addition, 75 μL of supernatant is removed from wells, cleared by centrifugation for 5 min at 1500 rpm, and stored at 4°C until assayed. Cells are returned to a 37°C incubator until 24 h after LPS addition, at which time 100 μL of supernatant is removed, cleared by centrifugation, and stored at 4°C. Supernatants are tested using ELISA kits for IL-1β, IL-6, IL-18, and IL-1α[1].
激酶实验: Enzyme inhibition is assayed by tracking of the rate of hydrolysis of an appropriate substrate labeled with either p-nitroaniline or aminomethyl coumarin (AMC) as follows: ICE/caspase-1, suc-YVAD-p-nitroanilide; caspase-4, Ac-WEHD-AMC; caspase-6, Ac-VEID-AMC; caspase-3, -7, -8, and -9, Ac-DEVD-AMC; and granzyme B, Ac-IEPD-AMC. Enzymes and substrates are incubated in a reaction buffer [10 mM Tris, pH 7.5, 0.1% (w/v) CHAPS, 1 mM dithiothreitol, and 5% (v/v) DMSO] for 10 min at 37°C. Glycerol is added to the buffer at 8% (v/v) for caspase-3, -6, and -9 and granzyme B to improve stability of enzymes. The rate of substrate hydrolysis is monitored using a fluorometer. Assays for cathepsin B and trypsin are performed[2].
体外活性: VX-765通过防止前脑星形胶质细胞中IL-1β的增加阻断大鼠体内的癫痫发生,而对后放电持续时间没有明显影响.在患有遗传性失神癫痫的成年大鼠体内注射3天VX-765后,通过选择性阻断IL-1β生物合成,明显降低累积持续时间,减少平均55%的棘慢波放电.50 mg/kg-200 mg/kg VX-765在急性癫痫小鼠模型中,通过延迟首次癫痫开始时间,并减少平均50%的癫痫发作次数以及64%的总持续时间,产生抗癫痫作用.200 mg/kg VX-765在胶原诱导的关节炎小鼠模型中,抑制60%脂多糖诱导的IL-1β产生,并导致炎症评分剂量依赖性明显降低,有效保护关节病变.
体内活性: VRT-043198会抑制IL-1β从外周血单个核细胞和全血中的释放,IC50分别为0.67 μM和1.9 μM。VX-765是一种口服可吸收的VRT-043198前药,显示出对ICE /半胱天冬酶-1和半胱天冬酶-4的有效抑制作用,Ki分别为0.8 nM和<0.6 nM。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: 5% DMSO+95% Saline : 4.65 mg/mL (9.14 mM, suspension)
Ethanol : 93 mg/mL (182.7 mM)
DMSO : 45 mg/mL (88.41 mM)
关键字: Inhibitor | VX 765 | VX765 | Belnacasan | inhibit | Caspase
相关产品: Taurodeoxycholic acid sodium hydrate | Excisanin A | Z-WEHD-FMK | Effusanin E | Soyasaponin Bb | 2',3'-Dehydrosalannol | Lucidenic acid B | SDZ 224-015 | Phenoxodiol | 5,7,4'-Trimethoxyflavone
相关库: Anti-Aging Compound Library | Drug Repurposing Compound Library | ReFRAME Related Library | Pyroptosis Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Human Metabolite Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library
猜你喜欢
感兴趣产品